Orexigen Therapeutics says FDA sets Jan. 31 review date for potential obesity drug Contrave

more images

more images

Orexigen says FDA sets Jan. 31 date for Contrave

SAN DIEGO — Orexigen Therapeutics received a Jan. 31 federal regulatory review date for its potential obesity treatment, the company said Thursday.

Orexigen’s drug Contrave is part of a wave of potential obesity treatments under review by the Food and Drug Administration. An FDA panel of experts is scheduled to make a recommendation on Vivus Inc.’s drug candidate Qnexa by July 15. Regulators are also reviewing Arena Pharmaceuticals Inc.’s application for Lorcaserin.

Shares of Orexigen Therapeutics Inc. closed at $4.67 Wednesday.